However, the asset faced a series of setbacks in 2024. The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s Dato-DXd, to be known as Datroway, for patients with certain advanced breast ...

Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

Now there are optional alternative cost percentages for developers of solar projects that use solar cells manufactured with domestically-produced wafers to appropriately recognize cost differentials ...

Key Laboratory for Micro-Nano Optoelectronic Devices of Ministry of Education, School of Physics and Electronics, Hunan University, Changsha 410082, China ...

enhanced reoperation of 6-inch to 12-inch wafers using industry-standard wafer cassettes and FOUPs, and can also support mobile robot and overhead transfers of wafers in those FOUPs. This is a ...

Japanese drugmaker Daiichi Sankyo (TYO: 4568) announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 (TA-MUC1) antibody, ...